Bedrijfsoverzicht
Cogent Biosciences, Inc. is a clinical-stage biotechnology entity dedicated to the development of precision therapies specifically engineered for genetically defined diseases. The company operates within the Healthcare sector, more precisely in the Biotechnology industry, a classification that signifies its focus on creating novel biological interventions rather than manufacturing consumer goods or services. As of the latest data, the company maintains a substantial market capitalization of $5.90B and employs a workforce of 258 individuals. These figures collectively position Cogent Biosciences as a significant capital-intensive player in the biotech landscape, where the $5.90B valuation reflects the high cost of clinical trials and the market's anticipation of future regulatory approvals for its lead product candidates, while the absence of reported annual revenue in the provided facts underscores the typical pre-commercialization phase common to many biotechnology firms at this stage of development.
Financiële gezondheid
The company reports Net Income (TTM) of $-328,936,992 and EBITDA of $-330,799,008, while Revenue (TTM) is listed as N/A, a combination that reveals a cost structure dominated by research and development expenses that far exceed any current commercial income. The reported Free Cash Flow stands at $-152,490,624, indicating that the company is consuming cash reserves rapidly to fund its operations and clinical programs rather than generating positive cash flow from sales. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which indicates that the company has not yet achieved profitability and is operating in a phase where revenue generation is secondary to the advancement of its pipeline. Regarding liquidity and leverage, the company holds $900.76M in cash against $238.80M in debt, supported by a Debt to Equity ratio of 37.52, suggesting a balance sheet that is leveraged but currently supported by a significant cash buffer relative to obligations. The Current Ratio is an exceptionally high 14.23, which indicates robust short-term liquidity and a strong ability to meet immediate financial obligations without distress. Furthermore, the Return on Equity is -73.7% and the Return on Assets is -32.9%, metrics that reveal that management is currently deploying capital into negative returns as the company prioritizes asset accumulation and clinical progress over immediate shareholder value creation through profits.
Waarderingsbeoordeling
The trailing twelve-month P/E Ratio is N/A, while the Forward P/E is -52.81, a discrepancy that implies earnings are currently negative and future earnings expectations have not yet materialized into a positive multiple based on current price-to-earnings logic. The Price to Book ratio stands at 10.71, indicating that the market is valuing the company at a significant premium over its book value, likely due to the intangible value of its intellectual property and clinical pipeline rather than tangible assets. Alternative valuation metrics such as Price to Sales (N/A) and EV/EBITDA (-15.98) suggest that traditional valuation methods are less applicable due to the lack of sales and negative earnings, pointing instead to a valuation driven by future potential rather than current financial performance. In terms of trading range, the stock has a 52-Week High of $43.73 and a 52-Week Low of $4.12, meaning the current market price fluctuates within this wide band, reflecting the high volatility typical of small-cap biotechnology stocks. The Beta is 0.47, which signifies that the stock price is less volatile than the broader market, moving with only about half the intensity of the overall market index despite the inherent risks associated with clinical-stage development.
Growth & Income
The Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, reflecting the fact that the company is not yet in a mature commercial phase where year-over-year percentage growth rates are standard metrics for analysis. Since the company does not pay a dividend, as evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, it does not distribute earnings to shareholders, implying that all available capital is reinvested directly into research, development, and clinical trial expansion. Consequently, the company's strategy focuses entirely on growth through product development and market penetration rather than providing income yields to investors. The overall growth and income profile is characterized by a reliance on capital markets for funding rather than organic cash flow or dividend distributions, creating a scenario where investor returns are entirely dependent on the successful commercialization of future therapies and a potential exit event.